Literature DB >> 22664165

Defining combined immunodeficiency.

Chaim M Roifman1, Raz Somech, Fotini Kavadas, Linda Pires, Amit Nahum, Ilan Dalal, Eyal Grunebaum.   

Abstract

BACKGROUND: Although the extreme condition of typical profound T-cell dysfunction (TD), severe combined immunodeficiency (SCID), has been carefully defined, we are currently in the process of better defining less typical T-cell deficiencies, which tend to present with autologous circulating T-cell combined immunodeficiency (CID). Because autologous cells might interfere with the outcome of bone marrow transplantation, protocols usually include conditioning regimens. Therefore it is important to define the numbers of autologous cells usually detected in patients with CID versus those with SCID.
OBJECTIVES: We sought to determine the number of circulating T cells in patients with SCID as opposed to those with CID, to study their function, and to evaluate their possible detection during newborn screening using T-cell receptor excision circle (TREC) analysis.
METHODS: Numbers of circulating CD3(+) T cells (as determined by means of flow cytometry), in vitro responses to PHA, and TREC levels, all measured at presentation, were compiled from the research charts of the entire cohort of patients followed prospectively for T-cell immunodeficiency at the Hospital for Sick Children. Clinical data were ascertained retrospectively from the patient's hospital charts.
RESULTS: One hundred three patients had CD3(+) determinations, and 80 of them had a genetic diagnosis. All patients considered to have typical SCID had CD3(+) T-cell counts of fewer than 500 cells/μL. Some variability was observed among different genotypes. In vitro responses to PHA were recorded in 88 patients, of whom 68 had a genetic diagnosis. All patients with low CD3(+) T-cell numbers (<500 cells/μL) also had markedly decreased responses to PHA (typical SCIDs). However, responses ranged widely in the groups of patients with TD who had more than 500 CD3(+) autologous circulating T cells per microliter. Although patients with Omenn syndrome and ζ chain-associated protein, 70 kDa (ZAP70), and purine nucleoside phosphorylase (PNP) deficiencies had low responses, patients with the p.R222C mutation in the IL-2 receptor γ(IL2RG) gene as well as IL-10 receptor and CD40 ligand deficiencies had normal or near-normal mitogen responses. Finally, 51 patients had TREC levels measured. All patients with typical SCID, Omenn syndrome, and ZAP70 deficiency had low TREC levels. In contrast, patients with mutations in forkhead box protein 3 (FOXP3), CD40 ligand (CD40L), and IL-10 receptor α(IL10RA), as well as patients with the p.R222C mutation in the IL2RG gene, had normal TREC levels.
CONCLUSION: Patients with typical SCID can be defined as having fewer than 500 circulating CD3(+) T cells. Most patients with autologous T cells still have profound TD, as defined by reduced in vitro function and thymus output. Some patients with conditions including TD have normal TREC levels and will therefore not be detected in a TREC-based newborn screening program.
Copyright © 2012 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22664165     DOI: 10.1016/j.jaci.2012.04.029

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  28 in total

Review 1.  Periodontal and other oral manifestations of immunodeficiency diseases.

Authors:  M E Peacock; R M Arce; C W Cutler
Journal:  Oral Dis       Date:  2016-10-10       Impact factor: 3.511

2.  Activating PI3Kδ mutations in a cohort of 669 patients with primary immunodeficiency.

Authors:  M Elgizouli; D M Lowe; C Speckmann; D Schubert; J Hülsdünker; Z Eskandarian; A Dudek; A Schmitt-Graeff; J Wanders; S F Jørgensen; B Fevang; U Salzer; A Nieters; S Burns; B Grimbacher
Journal:  Clin Exp Immunol       Date:  2015-11-09       Impact factor: 4.330

3.  DOCK2 Deficiency in a Patient with Hyper IgM Phenotype.

Authors:  Zahra Alizadeh; Marzieh Mazinani; Leila Shakerian; Mohammad Nabavi; Mohammad R Fazlollahi
Journal:  J Clin Immunol       Date:  2017-12-04       Impact factor: 8.317

4.  Novel MALT1 Mutation Linked to Immunodeficiency, Immune Dysregulation, and an Abnormal T Cell Receptor Repertoire.

Authors:  Shirly Frizinsky; Erez Rechavi; Ortal Barel; Rose H Najeeb; Shoshana Greenberger; Yu Nee Lee; Amos J Simon; Atar Lev; Chi A Ma; Guangping Sun; Sarah A Blackstone; Joshua D Milner; Raz Somech; Tali Stauber
Journal:  J Clin Immunol       Date:  2019-04-29       Impact factor: 8.317

5.  Insight into normal thymic activity by assessment of peripheral blood samples.

Authors:  Diti Machnes-Maayan; Atar Lev; Uriel Katz; David Mishali; Amir Vardi; Amos J Simon; Raz Somech
Journal:  Immunol Res       Date:  2015-03       Impact factor: 2.829

6.  Purine nucleoside phosphorylase deficiency presenting as severe combined immune deficiency.

Authors:  Raz Somech; Atar Lev; Galia Grisaru-Soen; Shelly I Shiran; Amos J Simon; Eyal Grunebaum
Journal:  Immunol Res       Date:  2013-05       Impact factor: 2.829

Review 7.  Primary immunodeficiency for the primary care provider.

Authors:  A W O'Keefe; M Halbrich; M Ben-Shoshan; C McCusker
Journal:  Paediatr Child Health       Date:  2016-03       Impact factor: 2.253

8.  TREC and KREC profiling as a representative of thymus and bone marrow output in patients with various inborn errors of immunity.

Authors:  M Dasouki; A Jabr; G AlDakheel; F Elbadaoui; A M Alazami; B Al-Saud; R Arnaout; H Aldhekri; I Alotaibi; H Al-Mousa; A Hawwari
Journal:  Clin Exp Immunol       Date:  2020-07-21       Impact factor: 4.330

9.  MHC II deficient infant identified by newborn screening program for SCID.

Authors:  Nufar Marcus; Tali Stauber; Atar Lev; Amos J Simon; Jerry Stein; Arnon Broides; Ido Somekh; Shlomo Almashanu; Raz Somech
Journal:  Immunol Res       Date:  2018-08       Impact factor: 2.829

10.  Combined immunodeficiency in the United States and Kuwait: Comparison of patients' characteristics and molecular diagnosis.

Authors:  Waleed Al-Herz; Luigi D Notarangelo; Ali Sadek; Rebecca Buckley
Journal:  Clin Immunol       Date:  2015-08-03       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.